Next Article in Journal
The Role of Ultrasonography in the Process of Weaning from Mechanical Ventilation in Critically Ill Patients
Previous Article in Journal
Validation of a New Digital and Automated Color Perception Test
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 14
Issue 4
10.3390/diagnostics14040397
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Artificial Intelligence in Kidney Disease: A Comprehensive Study and Directions for Future Research

by
Chieh-Chen Wu
1,
Md. Mohaimenul Islam
2,
Tahmina Nasrin Poly
3 and
Yung-Ching Weng
1,*
1
Department of Healthcare Information and Management, School of Health and Medical Engineering, Ming Chuan University, Taipei 111, Taiwan
2
Outcomes and Translational Sciences, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
3
Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan
*
Author to whom correspondence should be addressed.
Diagnostics 2024, 14(4), 397; https://doi.org/10.3390/diagnostics14040397
Submission received: 4 December 2023 / Revised: 3 February 2024 / Accepted: 5 February 2024 / Published: 12 February 2024
(This article belongs to the Special Issue Artificial Intelligence in Metabolic Diseases)
Browse Figures
Versions Notes

Abstract

:
Artificial intelligence (AI) has emerged as a promising tool in the field of healthcare, with an increasing number of research articles evaluating its applications in the domain of kidney disease. To comprehend the evolving landscape of AI research in kidney disease, a bibliometric analysis is essential. The purposes of this study are to systematically analyze and quantify the scientific output, research trends, and collaborative networks in the application of AI to kidney disease. This study collected AI-related articles published between 2012 and 20 November 2023 from the Web of Science. Descriptive analyses of research trends in the application of AI in kidney disease were used to determine the growth rate of publications by authors, journals, institutions, and countries. Visualization network maps of country collaborations and author-provided keyword co-occurrences were generated to show the hotspots and research trends in AI research on kidney disease. The initial search yielded 673 articles, of which 631 were included in the analyses. Our findings reveal a noteworthy exponential growth trend in the annual publications of AI applications in kidney disease. Nephrology Dialysis Transplantation emerged as the leading publisher, accounting for 4.12% (26 out of 631 papers), followed by the American Journal of Transplantation at 3.01% (19/631) and Scientific Reports at 2.69% (17/631). The primary contributors were predominantly from the United States (n = 164, 25.99%), followed by China (n = 156, 24.72%) and India (n = 62, 9.83%). In terms of institutions, Mayo Clinic led with 27 contributions (4.27%), while Harvard University (n = 19, 3.01%) and Sun Yat-Sen University (n = 16, 2.53%) secured the second and third positions, respectively. This study summarized AI research trends in the field of kidney disease through statistical analysis and network visualization. The findings show that the field of AI in kidney disease is dynamic and rapidly progressing and provides valuable information for recognizing emerging patterns, technological shifts, and interdisciplinary collaborations that contribute to the advancement of knowledge in this critical domain.

1. Introduction

Kidney disease remains a global public health concern due to its higher prevalence and rising incidence [1,2]. Existing challenges related to tackling the burden of kidney disease include late-stage diagnoses, limited treatment options for end-stage kidney disease (ESKD), and disparities in access to healthcare [3,4,5]. The asymptomatic nature of the disease in its initial stages often hinder early detection, leading to delayed interventions and higher mortality rates [6]. Individuals with ESKD have limited alternatives, primarily dialysis or transplantation. However, access to these options is hampered by geographic, financial, and organ availability constraints [7,8]. Prior research emphasized the critical need to promptly tackle these challenges by identifying patients in earlier stages [4,9]. Artificial intelligence (AI) has emerged as a revolutionary tool in healthcare, particularly in the early prediction of kidney disease [10]. AI technologies, including machine learning algorithms, have shown substantial capabilities in analyzing diverse sets of patient data, encompassing clinical records, imaging, and genetic information. Numerous studies have been conducted leveraging these models to predict the onset of kidney disease at early stages [11,12], which facilitates timely interventions and improved patient outcomes [13]. The higher accuracy of these models has a potential impact on reducing the burden of kidney disease. Integration of AI tools into real-world clinical practices represents a promising frontier in proactive healthcare management, offering novel approaches to predict and mitigate the impact of kidney disease at its earliest stages [14,15]. Given the dynamic and rapidly evolving nature of AI in kidney disease research, a bibliometric analysis proves invaluable in comprehensively assessing research trends over time. This method facilitates an objective evaluation of both the quantity and quality of research outputs, unveiling key thematic areas, influential authors, and impactful journals [16,17]. Through the application of bibliometric analysis, we gain insights into the most frequently explored topics at the intersection of AI and kidney disease, thereby assisting in the identification of research gaps and areas needed for further exploration. Additionally, understanding the global landscape of AI research in kidney disease is vital for fostering international collaborations and knowledge exchange. Therefore, this study aims to offer an up-to-date and extensive overview of AI research in the realm of kidney disease through the application of bibliometric analysis.

2. Methods

2.1. Search Strategy

We collected relevant articles from the Web of Science (WoS) Core Collection by Clarivate Analytics in the USA, as it offers a wide range of bibliometric indicators and encompasses literature from various disciplines [17,18,19]. We formulated our search strategy by screening search terms found in previously published articles and consulting with experts who have conducted bibliometric studies. The conclusive search was conducted on 20 November 2023, ensuring the inclusion of all relevant articles published between 1 January 2010 and 20 November 2023. We used search terms associated with (1) kidney disease and (2) artificial intelligence models, combining the terms using Boolean Operators (“OR”, “AND”) (Supplementary Table S1).

2.2. Inclusion and Exclusion

All journal articles related to the application of AI models in kidney disease were subject to screening. Articles were considered for inclusion in final analysis if they met the following criteria: (1) written in the English language, (2) focused on kidney disease, and (3) involved AI models. Given the dynamic nature of AI research with frequent updates, we included research or review articles from peer-reviewed journals, conference proceedings, and early access publications. However, editorial materials, book chapters, and books were excluded from the bibliometric analysis.

2.3. Screening Strategy

Two authors conducted an independent screening of titles and abstracts from the collected articles and verified their validity. Any disagreements at this stage were resolved through discussions. Finally, data from the selected articles were gathered and stored in **.txt formats.

2.4. Bibliometric Analysis

This study seeks to explore the following inquiries, aiming to build upon previous research on the utilization of AI in kidney diseases:
  • Which countries, institutions, sources, and authors exhibit the highest productivity in the field of AI applied to kidney disease?
  • What are the prominent research topics and themes in the application of AI to kidney disease?
  • What methods and keywords are mainly used in the existing body of literature?

2.4.1. Growth Rate of Publications

The calculation of the annual growth rate of publications involved determining the annual publication count, annual growth, and average growth rate of publications, employing the following methods:
A n n u a l   g r o w t h = T o t a l   n u m b e r   o f   a r t i c l e s   i n   c u r r e n t   y e a r − T o t a l   n u m b e r   o f   a r t i c l e s   i n   p r e v i o u s   y e a r  
A v e r a g e   g r o w h t   r a t e = [ ( N − N k − 1 ) ] N k − 1 × 100
where N is the total number of articles in the current year and N k − 1 is the total number articles in the previous year.

2.4.2. Publication Productivity

We analyzed publication trends, emphasizing the most prolific journals, countries, institutions, and authors. Specifically, we considered the top 10 most productive journals with categories, the top 10 most prolific countries with economic status, and the top 10 authors and institutions with countries. Rankings for countries, journals, institutions, and authors were determined based on the respective number of published articles.

2.4.3. Research Hot Spot Tendencies

The VOSviewer software (Version 1.6.20) from the Centre for Science and Technology Studies at Leiden University was used to create a network map and clusters based on publications from 2010 to 2023. Network maps for regions/countries, institutions, and keywords were generated and presented in various clusters. Each node in the network map is denoted by a labeled circle, with larger circles signifying higher frequencies. The color of each circle corresponds to its respective cluster, while the strength of associations between nodes is conveyed through the thickness and length of links.

3. Results

3.1. Search Findings

Figure 1 illustrates the flow of the search and screening process. The initial search yielded 673 articles, and after excluding 31 based on pre-defined inclusion criteria, the screening phase involved 642 articles. Ultimately, the final bibliometric analysis comprised 621 articles.

3.2. Overall Trends

The number of annual publications on the application of AI in the domain of kidney disease increased from one article in 2010 to one hundred and seventy-two articles in 2022 (Figure 2). Before 2015, the number of annual articles did not reach 10. The average annual growth rate of articles was a maximum of 65.38% in 2022 and showed an 8.33% decline in 2016 (Table 1).

3.3. Journals and Their Subject Categories

Overall, the papers were published by 324 different journals. As Table 2 shows, the Journal of Nephrology Dialysis Transplantation published the most papers (4.12%, 26/631 papers) followed by American Journal of Transplantation (3.01%, 19/631) and Scientific Reports (2.69%, 17/631).

3.4. Distribution of Source Countries/Regions

Examining the origin of research often involves considering the country of the corresponding author. In our analysis, we found authors representing 68 countries. The preeminent contributors were from the United States (n = 164, 25.99% of all published articles), followed by China (n = 156, 24.72%) and India (n = 62, 9.83%). Notably, a substantial majority of published articles, 94.13% (n = 594) originated from researchers based in these top ten countries (Table 3).
Figure 3 Illustrates the co-authorship analysis involving countries that published a minimum of five articles. The analysis reveals a total of six clusters, identified by distinct colors. For example: both cluster 1 (red color) and cluster 2 (green color), comprising six countries.

3.5. Distribution of Institutions

Based on our study findings, 1252 institutes actively contributed to at least one research article. Table 4 presents the top 10 research institutions that demonstrated notable productivity in the application of AI to kidney disease. Mayo Clinic led the list with 27 articles, followed by Harvard University with 19 articles, Sun Yat-Sen University with 16 articles, and Sichuan University with 15 articles.
Figure 4 illustrates the co-authorship analysis involving 58 institutions that have published a minimum of five articles. The analysis reveals a total of seven clusters, identified by distinct colors (cluster 1 in red, comprising twelve institutions; cluster 2 in green, including eleven institutions; and cluster 7 in aqua color, comprising two institutions).

3.6. Authors

In total, 3775 authors contributed to the 631 articles. The top 10 authors (Table 5) contributed to 124 articles (19.65% of all articles). Cheungpasitporn W. contributed to most papers (n = 16) followed by Thongprayoon C (n = 16), Leeaphorn N (n = 13), and Cooper M (n = 12).

3.7. Keywords

A total of 1139 keywords were employed in these studies, and the top 65 keywords were classified into five clusters through keyword-clustering analysis (Figure 5). The five most prevalent keywords included: (a) AI terms: machine learning (n = 169), deep learning (n = 47), artificial intelligence (n = 44), random forest (n = 20), and artificial neural network (n = 14); (b) diseases: chronic kidney/CKD (n = 132), lupus nephritis (n = 16), kidney transplant (n = 12), acute kidney injury (n = 8), and end-stage renal disease (n = 7); (c) process terms: prediction/prediction model (n = 33), classification (n = 14), clustering (n = 8), prognosis (n = 6), and diagnosis (n = 4).

3.8. Top Cited Articles

We investigated the utilization of AI in the realm of kidney disease research. In Table 6, we present the ten most cited articles, garnering a combined total of 683 citations, which were published from 2017 to 2021. The publication with the highest citation count, titled “Neural network and support vector machine for the prediction of chronic kidney disease: A comparative study”, which was published in Computers in Biology and Medicine in 2019, has amassed 104 citations as of 20 November 2023.

4. Discussion

Artificial intelligence (AI) has become a key driving force in the realm of kidney disease, making substantial contributions to its diagnosis, prognosis, and overall management. Nowadays, AI models leverage extensive datasets comprising patient records, imaging studies, and genetic information, demonstrating remarkable performance in predicting the early onset of kidney disease [30,31]. Furthermore, diagnostic tools developed by AI models enhance precision and efficiency in identifying renal abnormalities, thereby facilitating timely interventions. Through bibliometric analysis, this study identified and examined 631 articles focusing on the application of AI in kidney diseases. The analysis unveiled prevalent themes, influential authors, and high-impact journals, providing insights into the most frequently explored topics at the intersection of AI and kidney disease. There has been a noticeable increase in the number of articles focusing on the application of AI in kidney disease, especially after the year 2016. This study also used clustering algorithms to group nodes that share strong connections, creating distinct clusters within the network. The strength of the connections was determined by co-authorship frequency, co-citation strength, or keyword co-occurrence. These clusters are visually represented in varying colors, and the size of nodes acts as an indicator of the significance or centrality of entities within their respective clusters. These findings may help researchers to delve into these clusters, pinpoint influential nodes, and give valuable insights into thematic concentrations and collaborative patterns in the literature.
Our study found that the predominant contributors were from the United States, followed by China and India. Remarkably, nearly 95% of the published articles were authored by researchers from the top ten countries. Furthermore, a higher percentage of articles originated from developed nations (categorized by the World Bank) [32,33]. Notably, institutions in developed countries actively conducted research on the application of AI in the context of kidney disease [34]. Recently, low-income and developing countries have focused on AI research for disease management, addressing healthcare challenges more effectively [35]. However, researchers in these countries often encounter resource shortages and limited access to specialized medical expertise when developing AI models [36,37]. Despite these challenges, these nations are on their way to developing advance AI tools because automated diagnosis, patient monitoring, and treatment planning prove to be cost-effective. Such advancements hold the potential to narrow the healthcare disparity gap by providing scalable, accessible, and efficient tools. Additionally, AI enables the optimization of limited resources, offering more precise and personalized healthcare interventions [38,39]. Through a comprehensive effort in AI research, low-income countries can leverage innovative technologies to enhance early detection, improve patient outcomes, and establish sustainable strategies for managing kidney diseases within resource-constrained settings.
The Journal of Nephrology Dialysis Transplantation led in the number of published papers, followed by the American Journal of Transplantation and Scientific Reports. Additionally, it is worth highlighting that a significant proportion of articles were published in open-access journals and those with high impact factors. Research indicates that open-access journals generally receive higher citation rates compared to subscription-based journals due to their high accessibility and visibility [40,41]. Nowadays, researchers are increasingly opting for open-access platforms, enabling their work to reach a wider audience, including researchers, practitioners, and the public, particularly in low-income countries. The practice of freely sharing scholarly works not only facilitates broader knowledge dissemination but also attracts greater citation rates [42]. Additionally, it is evident that journals with high impact factors tend to garner more citations than those with lower impact factors [43,44]. It is primarily due to their perceived prestige and influence in the academic realm. High-impact-factor journals prioritize quality over quantity in research, attracting a broader readership and increasing the visibility of their content [45,46]. Researchers are more inclined to submit their work to and cite articles from journals with higher impact factors, as this enhances the visibility and impact of their own research.
Currently, AI is revolutionizing the healthcare landscape with advanced algorithms that significantly enhance physicians’ diagnostic capabilities [47,48]. Its transformative influence extends to the interpretation of complex clinical data, notably helping the diagnosis of kidney diseases at an early stage [49]. The predictive capabilities of AI models play a crucial role in effective healthcare management, facilitating the early identification of individuals at risk of developing kidney diseases [50,51] and enabling timely interventions [24,52]. Our findings show that random forest and artificial neural networks are commonly used algorithms for disease classification and prediction. Additionally, AI models are helping to develop personalized treatment strategies by tailoring interventions to individual patient profiles, aiming for optimized outcomes while minimizing adverse effects [53]. AI tools also hold promising potential in the monitoring of drug prescriptions for kidney diseases [54]. Given the complex nature of these conditions and the intricate interplay between medications and renal function, AI systems can play a crucial role in ensuring optimal drug management [55,56,57]. By leveraging big data, AI may identify patterns and predict potential adverse reactions, enabling healthcare providers to monitor drug prescriptions to individual patients with CKD or those at risk of AKI [52,58]. However, the use of AI for drug monitoring and clinical care is in its infancy [59,60]. The transformative impact of AI in healthcare, particularly in the domain of kidney disease diagnosis, holds the promise of enhanced patient care, more effective treatments, and improved overall health outcomes [30,61,62].
Ensuring the safety of kidney disease patients when utilizing AI is crucial to effectively leverage its potential benefits. Physicians must implement robust tools and measures to protect patients from unexpected errors made by AI tools [63]. Firstly, AI algorithms must be trained and validated with diverse and representative datasets to enhance accuracy and prevent biases [64]. Health care providers should establish stringent regulatory frameworks and standards for AI in healthcare, ensuring strict adherence to ethical guidelines and legal requirements [65]. The implementation of fail-safe mechanisms and human oversight is essential, enabling clinicians to intervene and rectify any erroneous decisions [66]. Physicians should conduct regular audits of AI tools, ensure transparency in decision-making processes, and engage in open communication with patients regarding the role of AI tools. These actions are decisive in building trust and addressing concerns, particularly within the context of kidney disease treatment. Healthcare policymakers should develop harmonized global frameworks to address patients’ privacy regarding patient data analysis. It is important to navigate the diverse legal landscapes, particularly between Europe and the USA, and develop robust anonymization techniques to ensure mitigation of privacy risks. Given the concern, developing clear and standardized guidelines for data sharing and processing across borders is pivotal, fostering trust and compliance with varying international regulations [67].
It is essential for healthcare providers to establish robust data security measures, protecting sensitive information and preserving privacy. The design of AI algorithms should prioritize accuracy and minimize biases by incorporating diverse and representative datasets during training [68]. Ensuring transparency in the decision-making process, including providing clear explanations of how conclusions are reached, remains crucial [69]. Additionally, strict adherence to ethical guidelines and legal requirements, such as data protection laws, is imperative to uphold integrity. AI tools should be monitored continuously to ensure their adaptability to evolving datasets and changing circumstances.
This bibliometric study on the application of AI in kidney disease has yielded novel and insightful findings. Our study has not only highlighted the increasing significance of AI in the field of kidney disease but has also revealed emerging trends, key contributors, and the evolution of research over time. Our findings have provided valuable insights into the specific areas within kidney disease research where AI has made substantial contributions, shedding light on the potential for enhanced diagnostic, prognostic, and therapeutic applications. These novel findings contribute to a deeper understanding of the intersection between AI and kidney disease, offering a foundation for future research directions and the continued advancement of AI technologies in the realm of renal health.

4.1. Strengths and Limitations

This study has several strengths. This is the first bibliometric study offering a robust method for evaluating the application of AI in kidney disease research, providing valuable insights into the strengths and trends within this dynamic field. Moreover, this study provides a broad overview of the existing research landscape, highlighting key trends, potential contributions, and emerging themes in the field. Indeed, this study provides a comprehensive understanding of the current state of AI in kidney disease, allowing researchers and policymakers to pinpoint areas of high impact and innovation. There are several limitations in our study that require acknowledgment. First, data for this study was collected from a single database, although it is a standard database for conducting bibliometric analyses in health research [70,71,72]. This database contains all relevant variables and includes high quality peer-reviewed journals. Second, it is possible that our search terms may have excluded certain articles; nevertheless, our search strategy was developed through discussions with other experts and a comprehensive review of previously published articles. Third, while we have presented the top 10 most highly cited articles, it is important to note that articles published earlier are likely to receive more citations. Unfortunately, we encountered challenges in presenting a standardized approach for evaluating highly cited articles on a yearly basis. Additionally, we were unable to provide a citation rate stratified by journals and publication date, which could have offered more precise insights into whether journals with higher impact factors tend to garner more citations. Lastly, our study only focused on articles published in English, meaning there is a potential oversight of valuable contributions to the topic published in other languages.

4.2. Future Directions

AI holds significant promise in transforming the management of kidney disease in the future through various applications and advancements. Here are several ways in which AI can contribute to kidney disease management (Table 7):
While the integration of AI in kidney disease management presents promising opportunities, it is essential to address challenges related to data privacy, ethical considerations, and the need for collaboration between healthcare professionals and AI systems to ensure safe and effective implementation.

5. Conclusions

This bibliometric study comprehensively examined the impact of AI on kidney disease research, providing a comprehensive overview of the field’s evolution. Through bibliometric analysis, this study identified key themes, influential authors, high-impact journals, and the most productive countries that have shaped the discourse on AI in kidney disease research. This bibliometric analysis contributes to a nuanced understanding of the progress and focal points in the field, guiding future research endeavors and fostering collaboration in the pursuit of innovative solutions for kidney disease care.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/diagnostics14040397/s1, Table S1: Search keywords.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Lv, J.-C.; Zhang, L.-X. Prevalence and disease burden of chronic kidney disease. Adv. Exp. Med. Biol. 2019, 1165, 3–15. [Google Scholar]
  2. Han, C.T.; Islam, M.M.; Poly, T.N.; Lu, Y.-C.; Lin, M.-C. A Meta-Analysis of Proton Pump Inhibitor Use and the Risk of Acute Kidney Injury: Geographical Differences and Associated Factors. J. Clin. Med. 2023, 12, 2467. [Google Scholar] [CrossRef] [PubMed]
  3. Luyckx, V.A.; Al-Aly, Z.; Bello, A.K.; Bellorin-Font, E.; Carlini, R.G.; Fabian, J.; Garcia-Garcia, G.; Iyengar, A.; Sekkarie, M.; Van Biesen, W. Sustainable development goals relevant to kidney health: An update on progress. Nat. Rev. Nephrol. 2021, 17, 15–32. [Google Scholar] [CrossRef]
  4. Borg, R.; Carlson, N.; Søndergaard, J.; Persson, F. The Growing Challenge of Chronic Kidney Disease: An Overview of Current Knowledge. Int. J. Nephrol. 2023, 2023, 9609266. [Google Scholar] [CrossRef] [PubMed]
  5. Wang, V.; Vilme, H.; Maciejewski, M.L.; Boulware, L.E. The economic burden of chronic kidney disease and end-stage renal disease. In Seminars in Nephrology; W. B. Saunders: Philadelphia, PA, USA, 2016; pp. 319–330. [Google Scholar]
  6. Chan, C.T.; Blankestijn, P.J.; Dember, L.M.; Gallieni, M.; Harris, D.C.; Lok, C.E.; Mehrotra, R.; Stevens, P.E.; Wang, A.Y.-M.; Cheung, M. Dialysis initiation, modality choice, access, and prescription: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019, 96, 37–47. [Google Scholar] [CrossRef] [PubMed]
  7. Evans, M.; Lewis, R.D.; Morgan, A.R.; Whyte, M.B.; Hanif, W.; Bain, S.C.; Davies, S.; Dashora, U.; Yousef, Z.; Patel, D.C. A narrative review of chronic kidney disease in clinical practice: Current challenges and future perspectives. Adv. Ther. 2022, 39, 33–43. [Google Scholar] [CrossRef]
  8. Braun, L.; Sood, V.; Hogue, S.; Lieberman, B.; Copley-Merriman, C. High burden and unmet patient needs in chronic kidney disease. Int. J. Nephrol. Renov. Dis. 2012, 5, 151–163. [Google Scholar]
  9. St. Clair Russell, J.; Boulware, L.E. End-stage renal disease treatment options education: What matters most to patients and families. In Seminars in Dialysis; Wiley-Blackwell: Oxford, UK, 2018; pp. 122–128. [Google Scholar]
  10. Zhao, J.; Gu, S.; McDermaid, A. Predicting outcomes of chronic kidney disease from EMR data based on Random Forest Regression. Math. Biosci. 2019, 310, 24–30. [Google Scholar] [CrossRef]
  11. Perotte, A.; Ranganath, R.; Hirsch, J.S.; Blei, D.; Elhadad, N. Risk prediction for chronic kidney disease progression using heterogeneous electronic health record data and time series analysis. J. Am. Med. Inform. Assoc. 2015, 22, 872–880. [Google Scholar] [CrossRef]
  12. Simonov, M.; Ugwuowo, U.; Moreira, E.; Yamamoto, Y.; Biswas, A.; Martin, M.; Testani, J.; Wilson, F.P. A simple real-time model for predicting acute kidney injury in hospitalized patients in the US: A descriptive modeling study. PLoS Med. 2019, 16, e1002861. [Google Scholar] [CrossRef]
  13. Bradley, R.; Tagkopoulos, I.; Kim, M.; Kokkinos, Y.; Panagiotakos, T.; Kennedy, J.; De Meyer, G.; Watson, P.; Elliott, J. Predicting early risk of chronic kidney disease in cats using routine clinical laboratory tests and machine learning. J. Vet. Intern. Med. 2019, 33, 2644–2656. [Google Scholar] [CrossRef]
  14. Diez-Sanmartin, C.; Sarasa-Cabezuelo, A.; Belmonte, A.A. The impact of artificial intelligence and big data on end-stage kidney disease treatments. Expert Syst. Appl. 2021, 180, 115076. [Google Scholar] [CrossRef]
  15. Kelly, C.J.; Karthikesalingam, A.; Suleyman, M.; Corrado, G.; King, D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019, 17, 195. [Google Scholar] [CrossRef]
  16. Kan, W.-C.; Chou, W.; Chien, T.-W.; Yeh, Y.-T.; Chou, P.-H. The most-cited authors who published papers in JMIR mHealth and uHealth using the authorship-weighted scheme: Bibliometric analysis. JMIR Mhealth Uhealth 2020, 8, e11567. [Google Scholar] [CrossRef] [PubMed]
  17. Pawassar, C.M.; Tiberius, V. Virtual reality in health care: Bibliometric analysis. JMIR Serious Games 2021, 9, e32721. [Google Scholar] [CrossRef] [PubMed]
  18. Poly, T.N.; Islam, M.M.; Walther, B.A.; Lin, M.C.; Li, Y.-C.J. Artificial intelligence in diabetic retinopathy: Bibliometric analysis. Comput. Methods Programs Biomed. 2023, 231, 107358. [Google Scholar] [CrossRef] [PubMed]
  19. Islam, M.M.; Poly, T.N.; Alsinglawi, B.; Lin, L.-F.; Chien, S.-C.; Liu, J.-C.; Jian, W.-S. Application of artificial intelligence in COVID-19 pandemic: Bibliometric analysis. Healthcare 2021, 9, 441. [Google Scholar] [CrossRef] [PubMed]
  20. Almansour, N.A.; Syed, H.F.; Khayat, N.R.; Altheeb, R.K.; Juri, R.E.; Alhiyafi, J.; Alrashed, S.; Olatunji, S.O. Neural network and support vector machine for the prediction of chronic kidney disease: A comparative study. Comput. Biol. Med. 2019, 109, 101–111. [Google Scholar] [CrossRef] [PubMed]
  21. Polat, H.; Danaei Mehr, H.; Cetin, A. Diagnosis of chronic kidney disease based on support vector machine by feature selection methods. J. Med. Syst. 2017, 41, 55. [Google Scholar] [CrossRef] [PubMed]
  22. Sabanayagam, C.; Xu, D.; Ting, D.S.; Nusinovici, S.; Banu, R.; Hamzah, H.; Lim, C.; Tham, Y.C.; Cheung, C.Y.; Tai, E.S.; et al. A deep learning algorithm to detect chronic kidney disease from retinal photographs in community-based populations. Lancet Digit. Health 2020, 2, e295–e302. [Google Scholar] [CrossRef] [PubMed]
  23. Xiao, J.; Ding, R.; Xu, X.; Guan, H.; Feng, X.; Sun, T.; Zhu, S.; Ye, Z. Comparison and development of machine learning tools in the prediction of chronic kidney disease progression. J. Transl. Med. 2019, 17, 119. [Google Scholar] [CrossRef]
  24. Zhang, K.; Liu, X.; Xu, J.; Yuan, J.; Cai, W.; Chen, T.; Wang, K.; Gao, Y.; Nie, S.; Xu, X.; et al. Deep-learning models for the detection and incidence prediction of chronic kidney disease and type 2 diabetes from retinal fundus images. Nat. Biomed. Eng. 2021, 5, 533–545. [Google Scholar] [CrossRef]
  25. Qin, J.; Chen, L.; Liu, Y.; Liu, C.; Feng, C.; Chen, B. A machine learning methodology for diagnosing chronic kidney disease. IEEE Access 2019, 8, 20991–21002. [Google Scholar] [CrossRef]
  26. Reeve, J.; Böhmig, G.A.; Eskandary, F.; Einecke, G.; Gupta, G.; Madill-Thomsen, K.; Mackova, M.; Halloran, P.F.; INTERCOMEX MMDx-Kidney Study Group. Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers. Am. J. Transplant. 2019, 19, 2719–2731. [Google Scholar] [CrossRef] [PubMed]
  27. Yoo, K.D.; Noh, J.; Lee, H.; Kim, D.K.; Lim, C.S.; Kim, Y.H.; Lee, J.P.; Kim, G.; Kim, Y.S. A machine learning approach using survival statistics to predict graft survival in kidney transplant recipients: A multicenter cohort study. Sci. Rep. 2017, 7, 8904. [Google Scholar] [CrossRef] [PubMed]
  28. Barbieri, C.; Cattinelli, I.; Neri, L.; Mari, F.; Ramos, R.; Brancaccio, D.; Canaud, B.; Stuard, S. Development of an artificial intelligence model to guide the management of blood pressure, fluid volume, and dialysis dose in end-stage kidney disease patients: Proof of concept and first clinical assessment. Kidney Dis. 2019, 5, 28–33. [Google Scholar] [CrossRef] [PubMed]
  29. Ma, F.; Sun, T.; Liu, L.; Jing, H. Detection and diagnosis of chronic kidney disease using deep learning-based heterogeneous modified artificial neural network. Future Gener. Comput. Syst. 2020, 111, 17–26. [Google Scholar] [CrossRef]
  30. Badidi, E. Edge AI for Early Detection of Chronic Diseases and the Spread of Infectious Diseases: Opportunities, Challenges, and Future Directions. Future Internet 2023, 15, 370. [Google Scholar] [CrossRef]
  31. Robinson, C.H.; Iyengar, A.; Zappitelli, M. Early recognition and prevention of acute kidney injury in hospitalised children. Lancet Child Adolesc. Health 2023, 7, 657–670. [Google Scholar] [CrossRef] [PubMed]
  32. Talbot, B.; Athavale, A.; Jha, V.; Gallagher, M. Data challenges in addressing chronic kidney disease in low-and lower-middle-income countries. Kidney Int. Rep. 2021, 6, 1503–1512. [Google Scholar] [CrossRef]
  33. Ameh, O.I.; Ekrikpo, U.; Bello, A.; Okpechi, I. Current management strategies of chronic kidney disease in resource-limited countries. Int. J. Nephrol. Renov. Dis. 2020, 13, 239–251. [Google Scholar] [CrossRef]
  34. Htay, H.; Alrukhaimi, M.; Ashuntantang, G.E.; Bello, A.K.; Bellorin-Font, E.; Gharbi, M.B.; Braam, B.; Feehally, J.; Harris, D.C.; Jha, V. Global access of patients with kidney disease to health technologies and medications: Findings from the Global Kidney Health Atlas project. Kidney Int. Suppl. 2018, 8, 64–73. [Google Scholar] [CrossRef] [PubMed]
  35. Ciecierski-Holmes, T.; Singh, R.; Axt, M.; Brenner, S.; Barteit, S. Artificial intelligence for strengthening healthcare systems in low-and middle-income countries: A systematic scoping review. NPJ Digit. Med. 2022, 5, 162. [Google Scholar] [CrossRef]
  36. Schwalbe, N.; Wahl, B. Artificial intelligence and the future of global health. Lancet 2020, 395, 1579–1586. [Google Scholar] [CrossRef] [PubMed]
  37. Guo, J.; Li, B. The application of medical artificial intelligence technology in rural areas of developing countries. Health Equity 2018, 2, 174–181. [Google Scholar] [CrossRef]
  38. Ahmed, Z.; Mohamed, K.; Zeeshan, S.; Dong, X. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database 2020, 2020, baaa010. [Google Scholar] [CrossRef] [PubMed]
  39. Noorbakhsh-Sabet, N.; Zand, R.; Zhang, Y.; Abedi, V. Artificial intelligence transforms the future of health care. Am. J. Med. 2019, 132, 795–801. [Google Scholar] [CrossRef]
  40. Holmberg, K.; Hedman, J.; Bowman, T.D.; Didegah, F.; Laakso, M. Do articles in open access journals have more frequent altmetric activity than articles in subscription-based journals? An investigation of the research output of Finnish universities. Scientometrics 2020, 122, 645–659. [Google Scholar] [CrossRef]
  41. Björk, B.-C.; Solomon, D. Open access versus subscription journals: A comparison of scientific impact. BMC Med. 2012, 10, 73. [Google Scholar] [CrossRef]
  42. Roux, D.J.; Rogers, K.H.; Biggs, H.C.; Ashton, P.J.; Sergeant, A. Bridging the science–management divide: Moving from unidirectional knowledge transfer to knowledge interfacing and sharing. Ecol. Soc. 2006, 11, 4. [Google Scholar] [CrossRef]
  43. Smith, M.J.; Weinberger, C.; Bruna, E.M.; Allesina, S. The scientific impact of nations: Journal placement and citation performance. PLoS ONE 2014, 9, e109195. [Google Scholar] [CrossRef] [PubMed]
  44. Tahamtan, I.; Safipour Afshar, A.; Ahamdzadeh, K. Factors affecting number of citations: A comprehensive review of the literature. Scientometrics 2016, 107, 1195–1225. [Google Scholar] [CrossRef]
  45. Owan, V.J. Research dissemination in action: A primer on the intricacies and politics of publishing in Scopus-indexed journals. SSRN Electron. J. 2023. [Google Scholar] [CrossRef]
  46. Rushforth, A.; de Rijcke, S. Accounting for impact? The journal impact factor and the making of biomedical research in the Netherlands. Minerva 2015, 53, 117–139. [Google Scholar] [CrossRef] [PubMed]
  47. Alowais, S.A.; Alghamdi, S.S.; Alsuhebany, N.; Alqahtani, T.; Alshaya, A.I.; Almohareb, S.N.; Aldairem, A.; Alrashed, M.; Bin Saleh, K.; Badreldin, H.A. Revolutionizing healthcare: The role of artificial intelligence in clinical practice. BMC Med. Educ. 2023, 23, 689. [Google Scholar] [CrossRef] [PubMed]
  48. Wiljer, D.; Hakim, Z. Developing an artificial intelligence–enabled health care practice: Rewiring health care professions for better care. J. Med. Imaging Radiat. Sci. 2019, 50, S8–S14. [Google Scholar] [CrossRef]
  49. Kumar, Y.; Koul, A.; Singla, R.; Ijaz, M.F. Artificial intelligence in disease diagnosis: A systematic literature review, synthesizing framework and future research agenda. J. Ambient Intell. Humaniz. Comput. 2022, 14, 8459–8486. [Google Scholar] [CrossRef]
  50. Yuan, Q.; Zhang, H.; Deng, T.; Tang, S.; Yuan, X.; Tang, W.; Xie, Y.; Ge, H.; Wang, X.; Zhou, Q. Role of artificial intelligence in kidney disease. Int. J. Med. Sci. 2020, 17, 970. [Google Scholar] [CrossRef]
  51. Sawhney, R.; Malik, A.; Sharma, S.; Narayan, V. A comparative assessment of artificial intelligence models used for early prediction and evaluation of chronic kidney disease. Decis. Anal. J. 2023, 6, 100169. [Google Scholar] [CrossRef]
  52. Yao, L.; Zhang, H.; Zhang, M.; Chen, X.; Zhang, J.; Huang, J.; Zhang, L. Application of artificial intelligence in renal disease. Clin. Ehealth 2021, 4, 54–61. [Google Scholar] [CrossRef]
  53. Alanazi, R. Identification and prediction of chronic diseases using machine learning approach. J. Healthc. Eng. 2022, 2022, 2826127. [Google Scholar] [CrossRef]
  54. Aiumtrakul, N.; Thongprayoon, C.; Suppadungsuk, S.; Krisanapan, P.; Miao, J.; Qureshi, F.; Cheungpasitporn, W. Navigating the landscape of personalized medicine: The relevance of ChatGPT, BingChat, and Bard AI in nephrology literature searches. J. Pers. Med. 2023, 13, 1457. [Google Scholar] [CrossRef]
  55. Nageeta, F.; Waqar, F.; Allahi, I.; Murtaza, F.; Nasir, M.; Danesh, F.; Irshad, B.; Kumar, R.; Tayyab, A.; Khan, M.S.M. Precision medicine approaches to diabetic kidney disease: Personalized interventions on the horizon. Cureus 2023, 15, e45575. [Google Scholar] [CrossRef]
  56. Yang, S.; Kar, S. Application of artificial intelligence and machine learning in early detection of adverse drug reactions (ADRs) and drug-induced toxicity. Artif. Intell. Chem. 2023, 1, 100011. [Google Scholar] [CrossRef]
  57. Pun, F.W.; Ozerov, I.V.; Zhavoronkov, A. AI-powered therapeutic target discovery. Trends Pharmacol. Sci. 2023, 44, 561–572. [Google Scholar] [CrossRef]
  58. Syrowatka, A.; Song, W.; Amato, M.G.; Foer, D.; Edrees, H.; Kuznetsova, M.; Dulgarian, S.; Seger, D.L.; Simona, A.; Bain, P.A. Key use cases for artificial intelligence to reduce the frequency of adverse drug events: A scoping review. Lancet Digit. Health 2022, 4, e137–e148. [Google Scholar] [CrossRef]
  59. Chaudhuri, S.; Long, A.; Zhang, H.; Monaghan, C.; Larkin, J.W.; Kotanko, P.; Kalaskar, S.; Kooman, J.P.; van der Sande, F.M.; Maddux, F.W. Artificial intelligence enabled applications in kidney disease. In Seminars in Dialysis; Wiley-Blackwell: Oxford, UK, 2021; pp. 5–16. [Google Scholar]
  60. Filler, G.; Gipson, D.S.; Iyamuremye, D.; de Ferris, M.E.D.G. Artificial Intelligence in Pediatric Nephrology—A Call for Action. Adv. Kidney Dis. Health 2023, 30, 17–24. [Google Scholar] [CrossRef] [PubMed]
  61. Rashed-Al-Mahfuz, M.; Haque, A.; Azad, A.; Alyami, S.A.; Quinn, J.M.; Moni, M.A. Clinically applicable machine learning approaches to identify attributes of chronic kidney disease (CKD) for use in low-cost diagnostic screening. IEEE J. Transl. Eng. Health Med. 2021, 9, 4900511. [Google Scholar] [CrossRef] [PubMed]
  62. Arif, M.S.; Mukheimer, A.; Asif, D. Enhancing the early detection of chronic kidney disease: A robust machine learning model. Big Data Cogn. Comput. 2023, 7, 144. [Google Scholar] [CrossRef]
  63. Challen, R.; Denny, J.; Pitt, M.; Gompels, L.; Edwards, T.; Tsaneva-Atanasova, K. Artificial intelligence, bias and clinical safety. BMJ Qual. Saf. 2019, 28, 231–237. [Google Scholar] [CrossRef] [PubMed]
  64. Nazer, L.H.; Zatarah, R.; Waldrip, S.; Ke, J.X.C.; Moukheiber, M.; Khanna, A.K.; Hicklen, R.S.; Moukheiber, L.; Moukheiber, D.; Ma, H. Bias in artificial intelligence algorithms and recommendations for mitigation. PLoS Digit. Health 2023, 2, e0000278. [Google Scholar] [CrossRef] [PubMed]
  65. Shneiderman, B. Bridging the gap between ethics and practice: Guidelines for reliable, safe, and trustworthy human-centered AI systems. ACM Trans. Interact. Intell. Syst. 2020, 10, 1–31. [Google Scholar] [CrossRef]
  66. Smith, H.; Fotheringham, K. Artificial intelligence in clinical decision-making: Rethinking liability. Med. Law Int. 2020, 20, 131–154. [Google Scholar] [CrossRef]
  67. Norori, N.; Hu, Q.; Aellen, F.M.; Faraci, F.D.; Tzovara, A. Addressing bias in big data and AI for health care: A call for open science. Patterns 2021, 2, 100347. [Google Scholar] [CrossRef]
  68. Liang, W.; Tadesse, G.A.; Ho, D.; Fei-Fei, L.; Zaharia, M.; Zhang, C.; Zou, J. Advances, challenges and opportunities in creating data for trustworthy AI. Nat. Mach. Intell. 2022, 4, 669–677. [Google Scholar] [CrossRef]
  69. Lepri, B.; Oliver, N.; Letouzé, E.; Pentland, A.; Vinck, P. Fair, transparent, and accountable algorithmic decision-making processes: The premise, the proposed solutions, and the open challenges. Philos. Technol. 2018, 31, 611–627. [Google Scholar] [CrossRef]
  70. Wu, C.-C.; Huang, C.-W.; Wang, Y.-C.; Islam, M.M.; Kung, W.-M.; Weng, Y.-C.; Su, C.-H. mHealth Research for Weight Loss, Physical Activity, and Sedentary Behavior: Bibliometric Analysis. J. Med. Internet Res. 2022, 24, e35747. [Google Scholar] [CrossRef]
  71. Shen, L.; Xiong, B.; Li, W.; Lan, F.; Evans, R.; Zhang, W. Visualizing collaboration characteristics and topic burst on international mobile health research: Bibliometric analysis. JMIR Mhealth Uhealth 2018, 6, e9581. [Google Scholar] [CrossRef]
  72. Tajudeen, F.P.; Bahar, N.; Maw Pin, T.; Saedon, N.I. Mobile technologies and healthy ageing: A bibliometric analysis on publication trends and knowledge structure of mHealth research for older adults. Int. J. Hum. Comput. Interact. 2022, 38, 118–130. [Google Scholar] [CrossRef]
Diagnostics 14 00397 g001
Figure 1. Screening flowchart for the application of artificial intelligence to kidney disease research.
Figure 1. Screening flowchart for the application of artificial intelligence to kidney disease research.
Diagnostics 14 00397 g001
Diagnostics 14 00397 g002
Figure 2. Publication outputs from 2010 to 2023 (Orange color bar represent partial year).
Figure 2. Publication outputs from 2010 to 2023 (Orange color bar represent partial year).
Diagnostics 14 00397 g002
Diagnostics 14 00397 g003
Figure 3. The network map among countries focusing on the application of artificial intelligence research in kidney disease, 2010–2023.
Figure 3. The network map among countries focusing on the application of artificial intelligence research in kidney disease, 2010–2023.
Diagnostics 14 00397 g003
Diagnostics 14 00397 g004
Figure 4. The network map among institutions focusing on the application of artificial intelligence research in kidney disease, 2010–2023.
Figure 4. The network map among institutions focusing on the application of artificial intelligence research in kidney disease, 2010–2023.
Diagnostics 14 00397 g004
Diagnostics 14 00397 g005
Figure 5. The co-occurrence network of the top 65 keywords in the application of AI in kidney disease research, 2010–2023.
Figure 5. The co-occurrence network of the top 65 keywords in the application of AI in kidney disease research, 2010–2023.
Diagnostics 14 00397 g005
Table 1. The distribution of articles by year between 2010 and 2023.
Table 1. The distribution of articles by year between 2010 and 2023.
YearNumberPercentageAnnual GrowthAnnual Growth Rate
201010.1610.00
201140.633300.00
201200.000−100.00
201360.956600.00
201430.48−3−50.00
2015121.909300.00
2016111.74−1−8.33
2017243.8013118.18
2018304.75625.00
2019568.872686.67
20207311.571730.36
202110416.483142.47
202217227.266865.38
202313521.3937−21.51
Table 2. Top 10 journals published papers in the application of artificial intelligence on kidney disease research.
Table 2. Top 10 journals published papers in the application of artificial intelligence on kidney disease research.
Rank Journal CountryCategoryRecord Count% of 631IF
1Nephrology Dialysis Transplantation EnglandUrology and nephrology264.126.1
2American Journal of Transplantation DenmarkTransplantation193.018.7
3Scientific ReportsEnglandMultidisciplinary 172.694.6
4Frontiers in MedicineSwitzerlandMedicine111.743.9
5IEEE AccessUSAComputer science 111.743.9
6Journal of Clinical MedicineSwitzerlandMedicine111.743.9
7PLOS OneUSAMultidisciplinary 111.743.7
8American Journal of Kidney DiseasesUSAUrology and nephrology91.4313.2
9DiagnosticsSwitzerland Medicine91.433.6
10Computer in Biology and Medicine USAComputer science and interdisciplinary application81.267.7
Table 3. Top 10 regions/countries publishing papers on the application of artificial intelligence in kidney disease research between 2010 and 2023.
Table 3. Top 10 regions/countries publishing papers on the application of artificial intelligence in kidney disease research between 2010 and 2023.
RankCountryNumberPercentage
1USA16425.99
2People’s Republic of China15624.72
3India629.83
4England386.02
5Italy345.39
6South Korea345.39
7Canada274.28
8Germany274.28
9Spain264.12
10Taiwan264.12
Table 4. Top 10 institutes publishing papers on the application of artificial intelligence in kidney disease research between 2010 and 2023.
Table 4. Top 10 institutes publishing papers on the application of artificial intelligence in kidney disease research between 2010 and 2023.
RankInstitutionsNumberPercentage
1Mayo Clinic274.27
2Harvard University193.01
3Sun Yat-Sen University162.53
4Sichuan University152.37
5University of California System152.37
6Harvard Medical School142.21
7Johns Hopkins University132.06
8Mayo Clinic Phoenix132.06
9Thammasat University 132.06
10Massachusetts General Hospital121.90
Table 5. Top 10 highly productive authors who published articles on the application of artificial intelligence in kidney disease research between 2010 and 2023.
Table 5. Top 10 highly productive authors who published articles on the application of artificial intelligence in kidney disease research between 2010 and 2023.
RankAuthorNumberPercentage
1Cheungpasitporn W162.54
2Thongprayoon C162.54
3Leeaphorn N132.06
4Cooper M121.90
5Jadlowiec CC121.90
6Mao MA121.90
7Pattharanitima P121.90
8Kaewput W111.74
9Mao SA111.74
10Vaitla P91.43
Table 6. Top 10 most cited published papers on the application of artificial intelligence in kidney disease research between 2010 and 2023.
Table 6. Top 10 most cited published papers on the application of artificial intelligence in kidney disease research between 2010 and 2023.
RankTitlesCitations
1 [20]Neural network and support vector machine for the prediction of chronic kidney disease: A comparative study. Computers in biology and medicine. 2019 Jun 1; 109:101–11104
2 [21]Diagnosis of chronic kidney disease based on support vector machine by feature selection methods. Journal of medical systems. 2017 Apr; 41:1–1.88
3 [22]A deep learning algorithm to detect chronic kidney disease from retinal photographs in community-based populations. The Lancet Digital Health. 2020 Jun 1;2(6): e295–302.77
4 [23]Comparison and development of machine learning tools in the prediction of chronic kidney disease progression. Journal of translational medicine. 2019 Dec;17(1):1–3.77
5 [24]Deep-learning models for the detection and incidence prediction of chronic kidney disease and type 2 diabetes from retinal fundus images. Nature biomedical engineering. 2021 Jun;5(6):533–45.72
6 [25]A machine learning methodology for diagnosing chronic kidney disease. IEEE Access. 2019 Dec 30; 8:20991–100259
7 [26]Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers. American Journal of Transplantation. 2019 Oct 1;19(10):2719–3157
8 [27]A machine learning approach using survival statistics to predict graft survival in kidney transplant recipients: A multicenter cohort study. Scientific reports. 2017 Aug 21;7(1):8904.57
9 [28]Development of an artificial intelligence model to guide the management of blood pressure, fluid volume, and dialysis dose in end-stage kidney disease patients: proof of concept and first clinical assessment. Kidney diseases. 2019 Feb 1;5(1):28–33.46
10 [29]Detection and diagnosis of chronic kidney disease using deep learning-based heterogeneous modified artificial neural network. Future Generation Computer Systems. 2020 Oct 1; 111:17–26.46
Table 7. Future applications of AI for kidney disease management.
Table 7. Future applications of AI for kidney disease management.
KeywaysProcess
Early detection and diagnosis To detect patterns and early signs of kidney disease.
To identify subtle biomarkers and risk factors that may not be immediately apparent to human clinicians.
Personalized treatment plansTo develop personalized treatment plans by considering individual patient data, including genetics, lifestyle, and treatment response.
To anticipate disease progression and tailor interventions accordingly
Optimizing medication managementTo enhance medication adherence by providing reminders, monitoring side effects, and adjusting dosages based on real-time patient data
To identify patients at higher risk of nonadherence and enable proactive interventions.
Remote patient monitoring To continuously monitor vital signs and other relevant health parameters, enabling remote patient monitoring.
Predictive analytics for complicationsTo predict complications associated with kidney disease, such as acute kidney injury, allowing for early intervention and prevention.
Efficient resource allocation To optimize resource allocation by predicting patient admission rates, identifying high-risk populations, and allocating resources accordingly.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wu, C.-C.; Islam, M.M.; Poly, T.N.; Weng, Y.-C. Artificial Intelligence in Kidney Disease: A Comprehensive Study and Directions for Future Research. Diagnostics 2024, 14, 397. https://doi.org/10.3390/diagnostics14040397

AMA Style

Wu C-C, Islam MM, Poly TN, Weng Y-C. Artificial Intelligence in Kidney Disease: A Comprehensive Study and Directions for Future Research. Diagnostics. 2024; 14(4):397. https://doi.org/10.3390/diagnostics14040397

Chicago/Turabian Style

Wu, Chieh-Chen, Md. Mohaimenul Islam, Tahmina Nasrin Poly, and Yung-Ching Weng. 2024. "Artificial Intelligence in Kidney Disease: A Comprehensive Study and Directions for Future Research" Diagnostics 14, no. 4: 397. https://doi.org/10.3390/diagnostics14040397

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop